Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 29, 2021 Category: Drugs & Pharmacology Source Type: news

Community-acquired bacterial meningitis
Progress has been made in the prevention and treatment of community-acquired bacterial meningitis during the past three decades but the burden of the disease remains high globally. Conjugate vaccines against the three most common causative pathogens (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae) have reduced the incidence of disease, but with the replacement by non-vaccine pneumococcal serotypes and the emergence of bacterial strains with reduced susceptibility to antimicrobial treatment, meningitis continues to pose a major health challenge worldwide. In patients presenting with bacterial m...
Source: Current Awareness Service for Health (CASH) - July 28, 2021 Category: Consumer Health News Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on September 29-30, 2021. The agenda will include discussions on cholera vaccine, hepatitis vaccines, herpes zoster vaccines, orthopoxvirus vaccine, pneumococcal vaccine, and tickborne encephalitis vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 26, 2021 Category: Rural Health Source Type: news

New Merck pneumonia vaccine OK'd in US weeks after Pfizer's
U.S. regulators have approved a new pneumonia vaccine from Merck, more than a month after OK'ing an improved version of rival Pfizer’s shot (Source: ABC News: Health)
Source: ABC News: Health - July 16, 2021 Category: Consumer Health News Tags: Health Source Type: news

FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults
KENILWORTH, N.J.--(BUSINESS WIRE)-- (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 16, 2021 Category: Drugs & Pharmacology Source Type: news

In Texas-Mexico Border Towns, COVID-19 Has Had an Unconscionably High Death Toll
Alfredo “Freddy” Valles was an accomplished trumpeter and a beloved music teacher for nearly four decades at one of the poorest middle schools in El Paso, Texas. He was known for buying his students shoes and bow ties for their band concerts, his effortlessly positive demeanor and his suave personal style—“he looked like he stepped out of a different era, the 1950s,” says his niece, Ruby Montana. While Valles was singular in life, his death at age 60 in February 2021 was part of a devastating statistic: He was one of thousands of deaths in Texas border counties—where coronavirus mortalit...
Source: TIME: Health - June 22, 2021 Category: Consumer Health News Authors: René Kladzyk, Phil Galewitz and Elizabeth Lucas | El Paso Matters and KHN Tags: Uncategorized COVID-19 Source Type: news

Twenty-Year Impact of Pneumococcal Conjugate Vaccines Twenty-Year Impact of Pneumococcal Conjugate Vaccines
A new report highlights the 20-year effect of pneumococcal conjugate vaccines in preventing pneumococcal disease in children.Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2021 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar) FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar)
The vaccine is capable of protecting against 20 serotypes involved in most cases of invasive pneumonia and pneumococcal disease in the US. This may be a significant advance in reducing pneumonia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2021 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older
First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia,1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pfizer begins testing COVID-19 booster shot with pneumococcal vaccine
The pharmaceutical company Pfizer is studying a third dose of the vaccine and a pneumococcal vaccine candidate. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2021 Category: Consumer Health News Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How a False Sense of Security, and a Little Secret Tea, Broke Down Taiwan ’s COVID-19 Defenses
All it took to break down the world’s most vaunted COVID-19 defense was a little secret tea. After almost 18 months of nearly unblemished success keeping the coronavirus pandemic at bay—including the world’s longest streak of case-free days—Taiwan is now in the grip of its first major COVID-19 surge. Total cases, which had been below 1,300 through the entire pandemic, have surged to more than 3,100 in the span of a week. Many offices have sent workers home, the streets of the capital Taipei have cleared out and the government has begun scrambling to secure vaccines to improve one of the worst inocul...
Source: TIME: Health - May 21, 2021 Category: Consumer Health News Authors: Michael Zennie and Gladys Tsai / Taipei Tags: Uncategorized COVID-19 feature overnight Taiwan Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Anthony Fauci, 100 Days Into the Biden Administration, Is Finally Getting to Do His Job
When Dr. Anthony Fauci arrived at 1600 Pennsylvania Ave. for his first White House press briefing under the new Biden Administration, he could see things would be different. It was the day after the Inauguration, and President Joe Biden was eager to get the country’s COVID-19 response back on track. Five minutes before he addressed the public, Fauci spoke with the new President. “He said, ‘I want you to just go and tell the science, explain to people that if we make mistakes, we’re going to fix the mistakes and we’re not going to dwell on the mistakes. Let science be communicated to the public...
Source: TIME: Health - May 18, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Pneumococcal Vaccines Safe for Pregnant Women With HIV Pneumococcal Vaccines Safe for Pregnant Women With HIV
Pneumococcal vaccines PCV-10 and PPV-23 are equally safe and immunogenic in pregnant women with HIV, although PPV-23 administration might be more beneficial because it includes a wider range of serotypes, researchers say.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

How Long Does the Pneumonia Vaccine Last
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 27, 2021 Category: General Medicine Source Type: news

World Immunization Week 2021
Vaccines bring us closer to a healthier world 22 April 2021 – The last week of April each year we celebrate the World Immunization Week. This year, the celebration amid the COVID-19 pandemic reminds us that vaccines can bring us closer to a healthier, more prosperous world, where no one suffers or dies from a vaccine-preventable disease. "Vaccines are one of the most effective public health interventions that have saved millions of lives over the years.This year, the importance of vaccination is clearer than ever. Safe and effective vaccines can be a game changer in the global response to the COVID-19 pandem...
Source: WHO EMRO News - April 22, 2021 Category: Middle East Health Source Type: news

What Are Toxin-Mediated Diseases?
Discussion A poison is a generic term for “a substance with an inherent property that tends to destroy life or impair health.” A toxin is more specific and is “any poison produced by an organism, characterized by antigenicity in certain animals and high molecular weight, and including the bacterial toxins that are the causative agents of tetanus, diphtheria, etc., and such plant and animal toxins as ricin and snake venom.” A toxin does not include those substances that are made synthetically produced. Venom is also a toxin that is used by animals and insects for predation or defense which can cause ...
Source: PediatricEducation.org - April 12, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

SII to start supplying 1st made-in-India pneumococcal conjugate vaccine to Centre from Wednesday
The SII has to supply 2.4 crore doses of the vaccine to the Health Ministry by December 2021. It will be sent to 37 consignees all over India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 6, 2021 Category: Pharmaceuticals Source Type: news

Dual influenza and pneumococcal vaccination cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Lawmakers: Require nursing homes to disclose vaccine data
Nursing homes have to publicly disclose their vaccination rates for flu and pneumonia, but there’s no similar mandate for COVID-19 shots (Source: ABC News: Health)
Source: ABC News: Health - March 25, 2021 Category: Consumer Health News Tags: Health Source Type: news

CT results in COVID-19 patients predict abnormal brain MRI findings
CT images of severe COVID-19 may help clinicians predict patients' vulnerabilit...Read more on AuntMinnie.comRelated Reading: Adenopathy may occur after COVID-19 vaccination Consider COVID-19 chest imaging patterns to prep for next pandemic Heart disease rare in pro athletes after COVID-19 CT plus deep learning distinguishes COVID-19 from other pneumonia Can AI predict COVID-19 hot spots from chest CT reports? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news

CT plus deep learning distinguishes COVID-19 from other pneumonia
A deep-learning algorithm improves CT's capability for distinguishing betwee...Read more on AuntMinnie.comRelated Reading: Can AI predict COVID-19 hot spots from chest CT reports? COVID-19 vaccine affects imaging results, researchers warn AI can predict need for steroid treatments in COVID-19 patients CT quantifies COVID-19 severity, ongoing conditions COVID-19, AI, and dose reduction top RSNA's CT agenda (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 3, 2021 Category: Radiology Source Type: news

Pneumococcal polysaccharide vaccine prevents ACS events in elderly, saves cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

COVID-19 Vaccination information for health care professionals, BTS
This document provides information for respiratory health care professionals in relation to the current COVID-19 vaccination programme and covers issues that may arise in discussion with patients. This might include questions around safety or immune responses from patients with chronic respiratory disease, or on immunosuppression for lung conditions as well as more general questions around vaccines/immunisation programme, including Influenza, and pneumococcal vaccines. We also highlight the role of respiratory healthcare professionals as advocates for vaccination. A significant constituency of patients may be fearful or ...
Source: Current Awareness Service for Health (CASH) - February 4, 2021 Category: Consumer Health News Source Type: news

What Are the Side Effects of the Pneumonia Vaccine?
Title: What Are the Side Effects of the Pneumonia Vaccine?Category: Diseases and ConditionsCreated: 2/4/2021 12:00:00 AMLast Editorial Review: 2/4/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - February 4, 2021 Category: Respiratory Medicine Source Type: news

Why Captain Sir Tom Moore did not take the vaccine: Family forced to speak out to clarify
CAPTAIN SIR TOM MOORE became a symbol of pride and courage in the face of the UK's darkest chapter in recent memory. Sir Tom, who raised more than £32m for the NHS, died after contracting pneumonia and testing positive for coronavirus. Did Sir Tom get vaccinated before his death? (Source: Daily Express - Health)
Source: Daily Express - Health - February 2, 2021 Category: Consumer Health News Source Type: news

Pneumococcal vaccination in adults with diabetes: modest effect on costs of pneumococcal disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, wit...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe CO...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
Receipt of PCV13 alone or in combination with PPSV23 predicts fivefold reduced risk for SPD compared with no vaccination (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 29, 2021 Category: Respiratory Medicine Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
THURSDAY, Jan. 28, 2021 -- For veterans with inflammatory bowel disease (IBD), the risk for severe pneumococcal disease (SPD) is increased with Crohn disease and with more comorbidities, and pneumococcal vaccination is associated with a reduced risk... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 28, 2021 Category: Pharmaceuticals Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Fewer Children Died in 2020, Despite the Pandemic. Experts Are Trying to Figure Out Why
Since the global pandemic began, one of the grimmer features of daily life has been watching the coronavirus death count tick up and up as the months have gone by. With so much unnecessary death in 2020, it’s surprising that in many countries, at least according to preliminary numbers, there was one significant group that actually saw its death rates fall: children. Data from the Human Mortality Database, a research project run by a global team of demographers, suggest that COVID-19 did not reverse years-long declines in child mortality, despite a mortality surge in the general population. Demographers, pediatricians...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news

Laws Promoting Flu Shot for Hospital Workers Can Cut Deaths
FRIDAY, Jan. 8, 2021 -- State laws promoting hospital worker vaccination against influenza may be effective for reducing monthly pneumonia and influenza mortality rates, especially among the elderly, according to a study published online Jan. 5 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2021 Category: Pharmaceuticals Source Type: news

If Covid-19 is Primarily a ‘First World’ Virus, Why is the Global South in Lockdown?
A lockdown closer home. Secretary-General Antonio Guterres walking the empty corridors of the UN Secretariat building in New York in 2020. Credit: United NationsBy Darini Rajasingham-SenanayakeCOLOMBO, Sri Lanka, Jan 7 2021 (IPS) The currently available Covid-19 vaccines have been authorized for ‘emergency use ‘in Europe and North America. This is due to an apparent spike in Covid-19 flu cases in the northern hemisphere as winter advances. Highly advertised vaccines are being produced and rolled out at ‘warped speed’ by powerful pharmaceutical and bio-technology companies headquartered in Euro-Ameri...
Source: IPS Inter Press Service - Health - January 7, 2021 Category: International Medicine & Public Health Authors: Darini Rajasingham-Senanayake Tags: Aid Development & Aid Editors' Choice Featured Global Headlines Health Human Rights IPS UN: Inside the Glasshouse Population Poverty & SDGs TerraViva United Nations Source Type: news

World prepares for muted New Year's Eve under Covid shadow
Britons urged to stay home; France puts 100,000 police out on patrol; Merkel laments hardest year; Times Square closed to publicSee all our coronavirus coverageMillions of people around the world are preparing for a New Year ’s Eve like no other – with lockdowns, restrictions and curfews in place in dozens of countries in an attempt to stem the spread of Covid-19 before vaccination drives start to take effect.New Year ’s Eve marks one year since the World Health Organization first mentioned a mysterious pneumonia inChina later identified as Covid-19, which went on in 2020 to kill more than 1.79 million pe...
Source: Guardian Unlimited Science - December 31, 2020 Category: Science Authors: Guardian staff and agencies Tags: Coronavirus UK news US news France Germany Australia news Europe Infectious diseases Science World news Source Type: news

Serum Institute launches India's first fully indigenously developed pneumococcal vaccine
PNEUMOSIL has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries. (Source: The Economic Times)
Source: The Economic Times - December 29, 2020 Category: Consumer Health News Source Type: news

Don ’t Let the Pandemic Stop Your Shots
Even as older adults await the coronavirus vaccine, many are skipping the standard ones. That ’s not wise, health experts say. (Source: NYT Health)
Source: NYT Health - December 28, 2020 Category: Consumer Health News Authors: Paula Span Tags: your-feed-science Whooping Cough Shingles (Disease) Diphtheria Coronavirus (2019-nCoV) Influenza Elderly Epidemics Drugs (Pharmaceuticals) Pneumonia your-feed-healthcare Vaccination and Immunization Hepatitis Tetanus Minorities Source Type: news

Vardhan launches India's first indigenously developed pneumococcal vaccine 'Pneumosil'
During clinical trials, Pneumosil was found to be safe and effective in the prevention of pneumonia and based on which Pneumosil has been licensed by the Drugs Controller General of India in July 2020 after approval from subject expert committee (SEC), he said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 28, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute develops first indigenous vaccine against pneumonia; to be launched next week
India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm. (Source: The Economic Times)
Source: The Economic Times - December 24, 2020 Category: Consumer Health News Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Special Topics - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Operations - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS: Journal of Emergency Medical Services News - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news